Randomized clinical trial to evaluate the effectiveness of enrofloxacin as a second‐line antibiotic for treatment of acute Escherichia coli mastitis

• Published in: Animal science journal 2018-07, Vol.89 (7), p.1033-1039
• Main Authors: Shinozuka, Yasunori, Kawai, Kazuhiro, Takeda, Akira, Yamada, Michiaki, Kayasaki, Fumi, Kondo, Nao, Sasaki, Yoshiko, Kanai, Nahoko, Mukai, Takuma, Sawaguchi, Naoki, Higuchi, Masaya, Kondo, Haruka, Sugimoto, Kouki, Yasuda, Akane, Watanabe, Aiko
• Format: Article
• Language: English
• Subjects: Acute Disease; Animals; Anti-Bacterial Agents - administration & dosage; Antibiotics; Appetite; Bacteria; Cattle; Cattle Diseases - drug therapy; Cattle Diseases - physiopathology; Clinical trials; Dairy cattle; Disease Progression; Drug Therapy, Combination; E coli; Enrofloxacin; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones - administration & dosage; Kanamycin; Kanamycin - administration & dosage; Mastitis; Mastitis - drug therapy; Mastitis - microbiology; Mastitis - physiopathology; Mastitis - veterinary; Oxytetracycline; Oxytetracycline - administration & dosage; prospective study; Recovery; Retreatment - methods; second‐line; Survival; Time Factors; Treatment Failure; Treatment Outcome
• ISSN: 1344-3941; 1740-0929
• DOI: 10.1111/asj.13025

The objective of the present study was to evaluate the effectiveness of enrofloxacin (ERFX) as a second‐line antibiotic for treatment of acute Escherichia coli (E. coli) mastitis. Forty‐two cows with naturally occurring acute E. coli mastitis were enrolled. On the first day of treatment (day 0), empirically selected antibiotics (oxytetracycline: n = 32, kanamycin: n = 10) were administered. Although systemic signs improved in 10 cows (first‐line group), the signs remained unchanged or worsened in 32 cows on day 1, including two cows that were found dead. The 30 surviving cows were randomly assigned to second‐line groups constituting an ERFX group (n = 19) or a control group (n = 11) that was treated with other antibiotics. Response to each treatment was evaluated by measuring clinical signs from day 0 to day 3, subsequent quarter milk recovery, and the 60‐day survival rate. Appetite on day 3 was significantly better in the ERFX group compared to the control group. No significant differences were observed in the 60‐day survival rate or the subsequent milk recovery between the ERFX group and the control group. Thus, the use of ERFX as a second‐line antibiotic for the treatment of acute E. coli mastitis could induce a rapid appetite recovery.